BACKGROUND: Airway smooth muscle (ASM) cells may contribute to the pathogenesis of asthma including airway inflammation and remodeling. We focused our study on the regulation of chemokine expression by cytokines and analyzed the mechanisms of eotaxin/CCL-11 expression in ASM cells. METHODS: Human ASM cells were cultured in vitro and treated with IL-4, interferon-gamma (IFNgamma), and tumor necrosis factor-alpha (TNFalpha). Secretion of chemokines into the culture medium was analyzed by ELISA. Expression of eotaxin mRNA was analyzed by reverse transcription-polymerase chain reaction (RT-PCR). Binding of transcription factor signal transducer activator of transcription (STAT) 6 to the eotaxin promoter-derived DNA was analyzed by pull-down Western blot. To assess transcriptional regulation of eotaxin, cells were transfected with eotaxin promoter-luciferase reporter plasmids, and activity was determined by dual luciferase assay. RESULTS: The Th2 cytokine IL-4 preferentially stimulated the expression of the CC chemokine receptor (CCR) 3-ligand chemokines eotaxin, eotaxin-3, and MCP-4. The Th1 cytokine IFNgamma stimulated the expression of chemokines IP-10 and RANTES. IL-4 stimulated nuclear translocation of signal transducer activator of transcription 6 (STAT6) and its binding to the eotaxin promoter region. IL-4 activated the eotaxin promoter and its activity was inhibited by mutation of the binding site for STAT6 in the promoter. CONCLUSIONS: The Th2 cytokine IL-4 preferentially stimulated the expression of CCR3 ligand chemokines including eotaxin in ASM cells. The transcription factor STAT6 may play a pivotal role in the activation of eotaxin transcription in response to IL-4.
BACKGROUND: Airway smooth muscle (ASM) cells may contribute to the pathogenesis of asthma including airway inflammation and remodeling. We focused our study on the regulation of chemokine expression by cytokines and analyzed the mechanisms of eotaxin/CCL-11 expression in ASM cells. METHODS:Human ASM cells were cultured in vitro and treated with IL-4, interferon-gamma (IFNgamma), and tumor necrosis factor-alpha (TNFalpha). Secretion of chemokines into the culture medium was analyzed by ELISA. Expression of eotaxin mRNA was analyzed by reverse transcription-polymerase chain reaction (RT-PCR). Binding of transcription factor signal transducer activator of transcription (STAT) 6 to the eotaxin promoter-derived DNA was analyzed by pull-down Western blot. To assess transcriptional regulation of eotaxin, cells were transfected with eotaxin promoter-luciferase reporter plasmids, and activity was determined by dual luciferase assay. RESULTS: The Th2 cytokine IL-4 preferentially stimulated the expression of the CC chemokine receptor (CCR) 3-ligand chemokines eotaxin, eotaxin-3, and MCP-4. The Th1 cytokine IFNgamma stimulated the expression of chemokines IP-10 and RANTES. IL-4 stimulated nuclear translocation of signal transducer activator of transcription 6 (STAT6) and its binding to the eotaxin promoter region. IL-4 activated the eotaxin promoter and its activity was inhibited by mutation of the binding site for STAT6 in the promoter. CONCLUSIONS: The Th2 cytokine IL-4 preferentially stimulated the expression of CCR3 ligand chemokines including eotaxin in ASM cells. The transcription factor STAT6 may play a pivotal role in the activation of eotaxin transcription in response to IL-4.
Authors: O Ghaffar; Q Hamid; P M Renzi; Z Allakhverdi; S Molet; J C Hogg; S A Shore; A D Luster; B Lamkhioued Journal: Am J Respir Crit Care Med Date: 1999-06 Impact factor: 21.405
Authors: K Ieki; S Matsukura; F Kokubu; T Kimura; H Kuga; M Kawaguchi; M Odaka; S Suzuki; S Watanabe; H Takeuchi; R P Schleimer; M Adachi Journal: Clin Exp Allergy Date: 2004-05 Impact factor: 5.018
Authors: S Matsukura; F Kokubu; M Kurokawa; M Kawaguchi; K Ieki; H Kuga; M Odaka; S Suzuki; S Watanabe; H Takeuchi; T Kasama; M Adachi Journal: Clin Exp Allergy Date: 2006-08 Impact factor: 5.018
Authors: S Matsukura; C Stellato; J R Plitt; C Bickel; K Miura; S N Georas; V Casolaro; R P Schleimer Journal: J Immunol Date: 1999-12-15 Impact factor: 5.422
Authors: Elizabeth L Hardaker; Alicia M Bacon; Karey Carlson; Amy K Roshak; James J Foley; Dulcie B Schmidt; Peter T Buckley; Meghan Comegys; Reynold A Panettieri; Henry M Sarau; Kristen E Belmonte Journal: FASEB J Date: 2003-11-03 Impact factor: 5.191
Authors: Guoping Li; John Fox; Zhigang Liu; Jun Liu; George F Gao; Yang Jin; Hongwei Gao; Min Wu Journal: J Immunol Date: 2013-10-14 Impact factor: 5.422
Authors: S Matsukura; M Odaka; M Kurokawa; H Kuga; T Homma; H Takeuchi; K Notomi; F Kokubu; M Kawaguchi; R P Schleimer; M W Johnson; M Adachi Journal: Clin Exp Allergy Date: 2010-03-04 Impact factor: 5.018
Authors: Amy M Spinelli; Yongfeng Liu; Li-Yan Sun; José C González-Cobos; Johannes Backs; Mohamed Trebak; Harold A Singer Journal: Pflugers Arch Date: 2015-06-20 Impact factor: 3.657
Authors: Chandrasekharam N Nagineni; Vijay K Kommineni; Nader Ganjbaksh; Krishnasai K Nagineni; John J Hooks; Barbara Detrick Journal: Aging Dis Date: 2015-11-17 Impact factor: 6.745